A Phase II MT-3724 Monotherapy Study in Relapsed and Refractory Diffuse-Large-B-Cell-Lymphoma Patients

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Nov 2020 According to a Molecular Templates media release, the FDA has placed MT-3724 clinical studies on partial clinical hold pending further review of a treatment-related fatality in a single subject in the Phase 2 monotherapy study.
04 Nov 2020 Status changed from recruiting to suspended, according to a Molecular Templates media release
06 Aug 2020 According to a Molecular Templates media release, COVID-19 pandemic has resulted in a significant slowdown in the pace of site initiations and patient enrollment and the company is working with sites to determine when a patient is suitable for study and to ensure the continued safety of all research participants.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com